A previous study from Ware et al., reported increased FGFR2 and FGFR3 mRNA levels in a panel of NSCLC cell lines with EGFR activating mutations treated with gefitinib [58]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.